UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

Scientific reports, 2021-04, Vol.11 (1), p.8976-8976, Article 8976

2021

Volltextzugriff (PDF)

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Nature medicine, 2021-11, Vol.27 (11), p.1904-1909

2021

Volltextzugriff (PDF)

Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer

Scientific reports, 2022-08, Vol.12 (1), p.14312-14312, Article 14312

2022

Volltextzugriff (PDF)

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

International journal of cancer, 2014-10, Vol.135 (8), p.1961-1969

2014

Volltextzugriff (PDF)

Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells

Genome research, 2017-08, Vol.27 (8), p.1312-1322

2017

Volltextzugriff (PDF)

MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells

OncoTargets and therapy, 2019-09, Vol.12, p.7675-7684

2019

Volltextzugriff (PDF)

Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211012982-17588359211012982

2021

Volltextzugriff (PDF)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

BMC medicine, 2022-10, Vol.20 (1), p.1-321, Article 321

2022

Volltextzugriff (PDF)

Landscape of somatic alterations in large-scale solid tumors from an Asian population

Nature communications, 2022-07, Vol.13 (1), p.4264-4264, Article 4264

2022

Volltextzugriff (PDF)

Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients

International journal of surgical pathology, 2023-09, Vol.31 (6), p.1075-1084

2023

Volltextzugriff (PDF)

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1947-1953

2013

Volltextzugriff (PDF)

Whole‐genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer

MedComm (2020), 2022-09, Vol.3 (3), p.e134-n/a

2022

Volltextzugriff (PDF)

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Nature communications, 2024-06, Vol.15 (1), p.5158-10

2024

Volltextzugriff (PDF)

Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor

Japanese journal of clinical oncology, 2015-02, Vol.45 (2), p.146-152

2015

Volltextzugriff (PDF)

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer

Thoracic cancer, 2023-01, Vol.14 (1), p.68-72

2023

Volltextzugriff (PDF)

PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer

Frontiers in cell and developmental biology, 2024-10, Vol.12, p.1430310

2024

Volltextzugriff (PDF)

De novo metastatic breast cancer: Subgroup analysis of molecular subtypes and prognosis

Oncology letters, 2020-04, Vol.19 (4), p.2884-2894

2020

Volltextzugriff (PDF)

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance

Discover. Oncology, 2023-10, Vol.14 (1), p.191-191, Article 191

2023

Volltextzugriff (PDF)

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer

Cancer chemotherapy and pharmacology, 2020-01, Vol.85 (1), p.205-215

2020

Volltextzugriff (PDF)

Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors

Cell reports. Medicine, 2024-09, Vol.5 (9), p.101707, Article 101707

2024

Volltextzugriff (PDF)

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

The lancet oncology, 2017-03, Vol.18 (3), p.371-383

2017

Volltextzugriff (PDF)

Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human

Frontiers in cell and developmental biology, 2021-08, Vol.9, p.716730-716730

2021

Volltextzugriff (PDF)

Interpretation of breast cancer screening guideline for Chinese women

Cancer biology & medicine, 2019-11, Vol.16 (4), p.825-835

2019

Volltextzugriff (PDF)

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer

Frontiers in oncology, 2022-04, Vol.12, p.778511-778511

2022

Volltextzugriff (PDF)

Transformation of Fonsecaea pedrosoi into sclerotic cells links to the refractoriness of experimental chromoblastomycosis in BALB/c mice via a mechanism involving a chitin-induced impairment of IFN-γ production

PLoS neglected tropical diseases, 2018-02, Vol.12 (2), p.e0006237-e0006237

2018

Volltextzugriff (PDF)

1 – 25 von 233

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(202)
Mit Volltextzugriff
(198)

Publikationsform

Sprache

Englisch
(230)
Chinesisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells

MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells

Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Landscape of somatic alterations in large-scale solid tumors from an Asian population

Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

Whole‐genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor

Real‐world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2− advanced breast cancer

PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer

De novo metastatic breast cancer: Subgroup analysis of molecular subtypes and prognosis

ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer

Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human

Interpretation of breast cancer screening guideline for Chinese women

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer

Transformation of Fonsecaea pedrosoi into sclerotic cells links to the refractoriness of experimental chromoblastomycosis in BALB/c mice via a mechanism involving a chitin-induced impairment of IFN-γ production

Suchergebnisse filtern